Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (321-330 of 477) with videos related to

Pageof 48
Sort By:
ACR Open Rheumatology|February 2, 2023
Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic SclerosisRobyn T Domsic, Robin Pokrzywinski, Larissa Stassek, et al.
Arthritis Research & Therapy|April 17, 2019
Study of MRI brain findings and carotid US features in systemic sclerosis patients, relationship with disease parametersRania M Gamal, Hanan Sayed M Abozaid, Mohmed Zidan, et al.
Rheumatology (Oxford, England)|March 15, 2025
Belumosudil in diffuse cutaneous systemic sclerosis: a randomised, double-blind, open-label extension, placebo-controlled, Phase 2 studyLorinda Chung, Richard M Silver, Virginia Steen, et al.
European Journal of Internal Medicine|September 22, 2019
The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offsCosimo Bruni, Edoardo Rosato, Vanessa Maestripieri, et al.
Clinical Therapeutics|July 16, 2003
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot studyMichael H Weisman, Larry W Moreland, Daniel E Furst, et al.
Rheumatology (Oxford, England)|May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosisChristopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
Arthritis Care & Research|October 1, 2020
Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study RegistryJeffrey R Curtis, Michael Weinblatt, Kenneth Saag, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2024
Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular SignaturesNancy Wareing, Xuan Wang, Lynette Keyes-Elstein, et al.
Seminars in Arthritis and Rheumatism|February 6, 2025
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based studyJulia Spierings, Giulia Bandini, Yannick Allanore, et al.
The Journal of Rheumatology|November 3, 2017
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group StudyVivien M Hsu, Christopher P Denton, Robyn T Domsic, et al.
Pageof 48

Showing results (321-330 of 477) with videos related to

Sort By:
Pageof 48
ACR Open Rheumatology|February 2, 2023
Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic SclerosisRobyn T Domsic, Robin Pokrzywinski, Larissa Stassek, et al.
Arthritis Research & Therapy|April 17, 2019
Study of MRI brain findings and carotid US features in systemic sclerosis patients, relationship with disease parametersRania M Gamal, Hanan Sayed M Abozaid, Mohmed Zidan, et al.
Rheumatology (Oxford, England)|March 15, 2025
Belumosudil in diffuse cutaneous systemic sclerosis: a randomised, double-blind, open-label extension, placebo-controlled, Phase 2 studyLorinda Chung, Richard M Silver, Virginia Steen, et al.
European Journal of Internal Medicine|September 22, 2019
The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offsCosimo Bruni, Edoardo Rosato, Vanessa Maestripieri, et al.
Clinical Therapeutics|July 16, 2003
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot studyMichael H Weisman, Larry W Moreland, Daniel E Furst, et al.
Rheumatology (Oxford, England)|May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosisChristopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
Arthritis Care & Research|October 1, 2020
Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study RegistryJeffrey R Curtis, Michael Weinblatt, Kenneth Saag, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2024
Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long-Term Normalization of Systemic Sclerosis Molecular SignaturesNancy Wareing, Xuan Wang, Lynette Keyes-Elstein, et al.
Seminars in Arthritis and Rheumatism|February 6, 2025
Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based studyJulia Spierings, Giulia Bandini, Yannick Allanore, et al.
The Journal of Rheumatology|November 3, 2017
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group StudyVivien M Hsu, Christopher P Denton, Robyn T Domsic, et al.
Pageof 48